Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

25.45
+0.70002.83%
Post-market: 25.450.00000.00%16:23 EDT
Volume:296.73K
Turnover:7.49M
Market Cap:699.90M
PE:-9.47
High:25.77
Open:25.17
Low:24.78
Close:24.75
Loading ...

Assertio Therapeutics (ASRT) Gets a Buy from Lake Street

TIPRANKS
·
13 Mar

JonesTrading Initiates Contineum Therapeutics at Buy With $23 Price Target

MT Newswires Live
·
13 Mar

Tempest Therapeutics Says Familial Adenomatous Polyposis Trial Gets US FDA 'Study May Proceed' Notice

MT Newswires Live
·
13 Mar

Pliant Therapeutics Signs Shareholder Rights Agreement

MT Newswires Live
·
13 Mar

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

GlobeNewswire
·
13 Mar

TransCode Therapeutics Says Safety Review Committee Approves Opening of Fourth Group in Phase 1 Trial to Treat Metastatic Cancers

MT Newswires Live
·
13 Mar

HLS Therapeutics Gets Green Light for Share Buyback Program

Dow Jones
·
13 Mar

Transcode Therapeutics’ fourth cohort in Phase 1/2 cancer trial approved

TIPRANKS
·
13 Mar

Indaptus Therapeutics FY24 EPS $(1.61) Up From $($1.83) YoY

Benzinga
·
13 Mar

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

PR Newswire
·
13 Mar

Indaptus Therapeutics reports FY24 EPS ($1.61) vs ($1.83) last year

TIPRANKS
·
13 Mar

This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year

Motley Fool
·
13 Mar

Press Release: Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Dow Jones
·
13 Mar

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

GlobeNewswire
·
13 Mar

Citigroup Initiates Coverage on Kymera Therapeutics With Buy Rating, $52 Price Target

MT Newswires Live
·
13 Mar

Press Release: HLS Therapeutics Announces Fiscal 2024 Financial Results and Normal Course Issuer Bid

Dow Jones
·
13 Mar